Boston Scientific Announces Executive and Director Changes
Ticker: BSX · Form: 8-K · Filed: Feb 12, 2025 · CIK: 885725
| Field | Detail |
|---|---|
| Company | Boston Scientific CORP (BSX) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, governance
Related Tickers: BSX
TL;DR
BSX board shake-up, new execs appointed.
AI Summary
Boston Scientific Corporation (BSX) announced on February 9, 2025, changes in its executive and director roles. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific names and dollar amounts related to these changes are not detailed in the provided excerpt.
Why It Matters
Changes in leadership and director roles can signal shifts in company strategy, governance, or future performance.
Risk Assessment
Risk Level: medium — Executive and director changes can introduce uncertainty regarding future strategy and operational direction.
Key Players & Entities
- Boston Scientific Corporation (company) — Registrant
- BSX (company) — Ticker Symbol
FAQ
What specific roles have been affected by the executive and director changes?
The filing indicates changes in the roles of certain officers and directors, including departures and elections of new directors, but does not specify the exact roles in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 9, 2025.
What is Boston Scientific Corporation's state of incorporation?
Boston Scientific Corporation is incorporated in Delaware.
What is the business address of Boston Scientific Corporation?
The business address is 300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234.
What is the SIC code for Boston Scientific Corporation?
The Standard Industrial Classification (SIC) code for Boston Scientific Corporation is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-02-12 16:09:19
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share BSX New York Stock
Filing Documents
- bsx-20250209.htm (8-K) — 26KB
- 0000885725-25-000009.txt ( ) — 185KB
- bsx-20250209.xsd (EX-101.SCH) — 3KB
- bsx-20250209_def.xml (EX-101.DEF) — 15KB
- bsx-20250209_lab.xml (EX-101.LAB) — 27KB
- bsx-20250209_pre.xml (EX-101.PRE) — 16KB
- bsx-20250209_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 9, 2025, Charles J. Dockendorff informed Boston Scientific Corporation (the "Company") that he will not stand for re-election at the Company's 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting"). Mr. Dockendorff has served as a member of the Board of Directors (the "Board") of the Company since April 2015 and currently serves as a member of the Audit Committee and the Risk Committee. Mr. Dockendorff will continue to serve as a director and in his committee roles until the 2025 Annual Meeting. Mr. Dockendorff's decision not to stand for re-election at the 2025 Annual Meeting is not the result of any disagreement with the Company. The Board and Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors to the Board following Mr. Dockendorff's departure is in the best interest of the Company. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 12, 2025 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary